Journal of Brain Tumors

Dr. Eduardo C Gonzalez Toledo is a Director of Neuroradiology and Research, Department of Radiology at LSU Health Sciences Center Shreveport, United States of America. He was Director of the Residency Program of Radiology at the University Of Buenos Aires School Of Medicine. He was also appointed in the Evaluation Committee for the Medical Residency Program in Radiology. He was the first President of the Argentinean Association of Neuroradiology, President of the Iberolatin american Society of Neuroradiology. He has 34 Chapters in books, 164 papers, 365 lectures in meetings and 196 lectures in Courses. Dr. Eduardo C Gonzalez research interests are neuroradiology, Nuclear Medicine, Magnetic resonance, functional magnetic resonance, neuropathology brain tumours, cognitive changes in patients with brain tumours, neurological changes in patients with brain tumours, legal aspects brain tumours diagnosis and treatment.

Terry Lichtor, MD, PhD is a Clinical Professor, Medical College of Wisconsin, Medical School Regional Campus–Central Wisconsin,United States of America. He has a number of research interests, and his brain tumor work is largely focused on the development of a DNA vaccine for treatment of primary and metastatic intracerebral tumors. In particular Dr. Lichtor has shown that vaccines prepared by transfer of DNA from the tumor into a highly immunogenic cell line stimulates an antitumor immune response which may be efficacious in the treatment of patients with brain tumors. Other research interests include developing a passive immunotherapeutic strategy for treatment of Alzheimer’s Disease. In addition, he has been involved in the development of a non-invasive MRI technique to measure intracranial pressure and brain compliance, and has been exploring the efficacy of this modality in managing a variety of patients with neurologic problems where intracranial pressure is an issue. Dr. Lichtor is a member of the neurosurgery faculty at Rush University Medical Center in Chicago, Illinois.

Dr. Nhan L Tran is a Professor in the Department of Research and Cancer Biology at Mayo Clinic Arizona, USA. Dr. Tran's research has been focused on determining the cellular and biochemical mechanisms of action of candidate genes expressed in highly invasive glioblastoma cells and their matrix of aberrant signaling to discover points of convergence that can serve as targets of vulnerability for therapeutic intervention. He has identified and characterized certain members of the super family of cytokine receptors, the tumor necrosis factor receptors (TNFR) and their downstream signals via RhoGTPases to play important roles in modulating glioblastoma cell adhesion, invasion and cell survival. In addition, Dr. Tran's expertise also lies in high-throughput assay development, and applying molecular chemical libraries screens to exploit novel GBM targets as innovative strategies to treat invasive glioblastoma. His Research Interest are Precision medicine in brain tumours, Therapeutic resistance of invasive glioblastoma cells, Mechanism of Glioblastoma Invasion, Identification of novel targets and therapeutic development of novel therapies for invasive glioma.

Dr. Vita Golubovskaya is a Director of Research and Development at Promab Biotechnologies developing novel anti-cancer immunotherapies including CAR-T therapy. She has more than 20 years of experience in cancer research, oncology and immunology. Previously, Dr. Golubovskaya was a Research Associate Professor at Roswell Park Cancer Institute and Research Professor at University of Buffalo, SUNY, Buffalo, NY. She holds Ph.D from Institute of Cytology, St. Petersburg, Russia. Dr. Golubovskaya authored more than 75 manuscripts, 8 patents and several book chapters. She was awarded Susan Komen Grant for Breast Cancer studes as a Principal Investigator, NCI NIH grants as Co-Investigator and STTR grant as PI. Dr. Golubovskaya served as a Guest Editor in Frontiers in Bioscience, Anti-Cancer Agents in Medicinal Chemistry and Cancers. She is an Active Member of AACR.

Dr. Xianquan Zhan is a Professor at Xiangya Hospital of Central South University in China . Dr. Zhan received his undergraduate and graduate training in the fields of preventive medicine and epidemiology and statistics at the West China University of Medical Sciences in China. He received his post-doctoral training in oncology and cancer proteomics for two years at the Cancer Research Institute of Human Medical University in China. In 2001, he went to the University of Tennessee Health Science Center (UTHSC) in USA, where he was a post-doctoral researcher and focused on mass spectrometry and cancer proteomics. Then, he was appointed as an Assistant Professor of Neurology, UTHSC in 2005. He moved to the Cleveland Clinic in USA as a Project Scientist/Staff in 2006 where he focused on the studies of eye disease proteomics and biomarkers. He returned to UTHSC as an Assistant Professor of Neurology in the end of 2007, engaging in proteomics and biomarker studies of lung diseases and brain tumors, and initiating the studies of predictive, preventive, and personalized medicine (PPPM) in cancer. In 2010, he was promoted to Associate Professor of Neurology, UTHSC. His current main research interest focuses on the studies of cancer proteomics and biomarkers, and the use of modern omics techniques and systems biology for PPPM in cancer.